{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:02:10Z","timestamp":1776801730737,"version":"3.51.2"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>To study the efficacy and safety of Polyethylene glycolated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the prevention of neutropenia during concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. Participants were divided into an experimental group and a control group. The experimental group received PEG-rhG-CSF injections post-chemotherapy cycles, whereas the control group received standard care without additional intervention. Outcomes assessed included grade 3\/4 neutropenia incidence, blood cell count changes, febrile neutropenia rates, delays or interruptions in chemotherapy\/radiotherapy due to hematological toxicity, oral mucositis incidents, and bone pain occurrences, comparing these between both groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>1. 88 patients with locally advanced NPC were included, the incidence of grade 3 neutropenia in the experimental group was lower than that in the control group (P = 0.026); 2. The white blood cell count and neutrophil count in D7, D10, D14, and D21 in the experimental group were higher than those in the control group (P&lt;0.01); 3. The rate of delayed chemotherapy in the experimental group was lower than that in the control group (2.3% vs. 29.5%), P = 0.001; the rate of interruption of radiotherapy in the experimental group was lower than that in the control group (2.3% vs.27.3%), P = 0.003; 4. The incidence of bone pain in the experimental group was 34.1%, of which most were mild bone pain, and no severe bone pain occurred. The leukocyte and neutrophil counts of the patients in the bone pain group were significantly higher than those of the patients in the no bone pain group, P(WBC) = 0.001, P(ANC) = 0.002.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0315001","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:43:52Z","timestamp":1736966632000},"page":"e0315001","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Study of PEG-rhG-CSF for the prevention of neutropenia in concurrent chemoradiotherapy for nasopharyngeal carcinoma"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-6259","authenticated-orcid":true,"given":"Lu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobo","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"3","key":"pone.0315001.ref001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10192","key":"pone.0315001.ref002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma[J]","volume":"394","author":"YP Chen","year":"2019","journal-title":"Lancet"},{"key":"pone.0315001.ref003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40880-016-0103-5","article-title":"A new prognostic histopathologic classification of nasopharyngeal carcinoma[J]","volume":"35","author":"HY Wang","year":"2016","journal-title":"Chin J Cancer"},{"issue":"1","key":"pone.0315001.ref004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2005.12.003","article-title":"Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution[J]","volume":"65","author":"JL Yi","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"pone.0315001.ref005","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Y Sun","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"pone.0315001.ref006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial[J]","volume":"13","author":"L Chen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"pone.0315001.ref007","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2018.0026","article-title":"NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018[J]","volume":"16","author":"AD Colevas","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"pone.0315001.ref008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours[J]","volume":"201147","author":"MS Aapro","year":"2010","journal-title":"Eur J Cancer"},{"issue":"11","key":"pone.0315001.ref009","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials[J]","volume":"23","author":"L Wang","year":"2015","journal-title":"Support Care Cancer"},{"issue":"2","key":"pone.0315001.ref010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0360-3016(92)90768-D","article-title":"Loss of local control with prolongation in radiotherapy[J]","volume":"23","author":"JF Fowler","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"pone.0315001.ref011","doi-asserted-by":"crossref","first-page":"e0218627","DOI":"10.1371\/journal.pone.0218627","article-title":"Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB\/C non-small-cell lung carcinoma patients: Analysis of 956 patients[J]","volume":"14","author":"E PTopkan","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"pone.0315001.ref012","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ijrobp.2016.08.046","article-title":"The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer[J]","volume":"96","author":"T Shaikh","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"pone.0315001.ref013","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/172.6.1573","article-title":"Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response[J]","volume":"172","author":"WC Liles","year":"1995","journal-title":"J Infect Dis"},{"issue":"11","key":"pone.0315001.ref014","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V78.11.2791.bloodjournal78112791","article-title":"Granulocyte colony-stimulating factor and its receptor[J]","volume":"78","author":"GD Demetri","year":"1991","journal-title":"Blood"},{"issue":"19","key":"pone.0315001.ref015","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1056\/NEJMra052706","article-title":"Lineage-specific hematopoietic growth factors[J]","volume":"354","author":"K. Kaushansky","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0315001.ref016","first-page":"731","article-title":"Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia[J]","volume":"48","author":"JE Frampton","year":"1994","journal-title":"Drugs"},{"issue":"4","key":"pone.0315001.ref017","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00277-003-0628-y","article-title":"Clinical applications of granulocyte colony-stimulating factor: an update and summary[J]","volume":"82","author":"K H\u00fcbel","year":"2003","journal-title":"Ann Hematol"},{"issue":"9","key":"pone.0315001.ref018","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nri.2017.53","article-title":"Adult haematopoietic stem cell niches[J]","volume":"17","author":"GM Crane","year":"2017","journal-title":"Nature Reviews Immunology"},{"issue":"2","key":"pone.0315001.ref019","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","article-title":"Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review[J]","volume":"23","author":"AM Pfeil","year":"2015","journal-title":"Support Care Cancer"},{"issue":"5","key":"pone.0315001.ref020","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/jps.20024","article-title":"Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats[J]","volume":"93","author":"BB Yang","year":"2004","journal-title":"J Pharm Sci"},{"issue":"5","key":"pone.0315001.ref021","first-page":"695","article-title":"Phase I clinical pharmacokinetic and pharmacodynamic study of polyethylene glycol recombinant human granulocyte colony-stimulating factor injection[J]","volume":"28","author":"ZHANG HAN Xiaohong","year":"2012","journal-title":"Chinese Journal of Pharmacology"},{"issue":"4","key":"pone.0315001.ref022","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10637-014-0068-7","article-title":"An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects[J]","volume":"32","author":"KH Shin","year":"2014","journal-title":"Invest New Drugs"},{"issue":"4","key":"pone.0315001.ref023","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0169-409X(02)00023-6","article-title":"Mono-N-terminal poly(ethylene glycol)-protein conjugates[J]","volume":"54","author":"O Kinstler","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"pone.0315001.ref024","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics[J]","volume":"40","author":"JM Harris","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"pone.0315001.ref025","first-page":"495","article-title":"Phase I clinical tolerability trial of polyethylene glycolized recombinant human granulocyte colony-stimulating factor for injection[J]","volume":"25","author":"LIU SHI Yuan-kai","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"pone.0315001.ref026","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3892\/etm.2014.2160","article-title":"Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia[J]","volume":"9","author":"FP Wu","year":"2015","journal-title":"Exp Ther Med"},{"issue":"4","key":"pone.0315001.ref027","first-page":"307","article-title":"Value of PEGylated recombinant human granulocyte colony-stimulating factor for chemotherapy in ovarian and cervical cancer [J]","volume":"39","author":"M Yu","year":"2017","journal-title":"Zhejiang Medicine"},{"key":"pone.0315001.ref028","doi-asserted-by":"crossref","first-page":"754366","DOI":"10.3389\/fphar.2021.754366","article-title":"Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data[J]","volume":"12","author":"J Zhao","year":"2022","journal-title":"Front Pharmacol"},{"issue":"17","key":"pone.0315001.ref029","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/1759-7714.14544","article-title":"PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study[J]","volume":"13","author":"XS Sun","year":"2022","journal-title":"Thorac Cancer"},{"issue":"12","key":"pone.0315001.ref030","doi-asserted-by":"crossref","first-page":"12055","DOI":"10.21037\/apm-21-3209","article-title":"Prophylactic administration of mecapegfilgrastim after chemotherapy in patients with lymphoma[J]","volume":"10","author":"M Zheng","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"7","key":"pone.0315001.ref031","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline","volume":"39","author":"YP Chen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0315001.ref032","first-page":"333","article-title":"Radiation Oncology Therapy Branch of Chinese Medical Association, Radiation Therapy Committee of China Anti-Cancer Association. Chinese expert consensus on the use of polyethylene glycolized recombinant human granulocyte stimulating factor during simultaneous radiotherapy (2023)[J]","volume":"30","author":"Radiation Oncology Therapy Physicians Branch of Chinese Physicians Association","year":"2023","journal-title":"Chinese Journal of Cancer Prevention and Control"},{"issue":"7","key":"pone.0315001.ref033","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma[J]","volume":"97","author":"AT Chan","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"pone.0315001.ref034","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial[J]","volume":"145","author":"WF Li","year":"2019","journal-title":"Int J Cancer"},{"issue":"5","key":"pone.0315001.ref035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of pegfilgrastim[J]","volume":"50","author":"BB Yang","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"pone.0315001.ref036","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.21037\/apm-21-1400","article-title":"Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis[J]","volume":"10","author":"X Gu","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"4","key":"pone.0315001.ref037","first-page":"386","article-title":"Study of polyethylene glycol recombinant human granulocyte colony-stimulating factor to prevent neutropenia after concurrent chemoradiotherapy for head and neck tumors[J]","author":"F Liu","year":"2015","journal-title":"The Chinese Journal of Clinical Health Care"},{"key":"pone.0315001.ref038","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2407-8-195","article-title":"A single dose of pegfilgrastim compared with daily filgrastim for supporting eutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial[J]","volume":"8","author":"J Sierra","year":"2008","journal-title":"BMC Cancer"},{"issue":"14","key":"pone.0315001.ref039","first-page":"3710","article-title":"Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats[J]","volume":"51","author":"H Tanaka","year":"1991","journal-title":"Cancer Res"},{"issue":"4","key":"pone.0315001.ref040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.1052","article-title":"Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25\u20138315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim[J]","volume":"66","author":"P van Der Auwera","year":"2001","journal-title":"Am J Hematol"},{"issue":"5","key":"pone.0315001.ref041","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMc061587","article-title":"Lineage-specific hematopoietic growth factors[J]","volume":"355","author":"DC Dale","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0315001.ref042","first-page":"240","article-title":"Cohort study of PEG-rhG-CSF for primary prevention during concurrent chemoradiotherapy for cervical cancer [J]","volume":"41","author":"Z Mei","year":"2020","journal-title":"Journal of Wuhan University (Medical Edition)"},{"issue":"4","key":"pone.0315001.ref043","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00043426-199124000-00004","article-title":"Human granulocyte colony-stimulating factor: its basic aspects and clinical applications[J]","volume":"13","author":"S. Asano","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"2","key":"pone.0315001.ref044","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/02841868809090333","article-title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy[J]","volume":"27","author":"HR Withers","year":"1988","journal-title":"Acta Oncol"},{"issue":"3","key":"pone.0315001.ref045","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0360-3016(97)00339-8","article-title":"The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma[J]","volume":"39","author":"DL Kwong","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0315001.ref046","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.oraloncology.2018.10.006","article-title":"Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients[J]","volume":"86","author":"E Orlandi","year":"2018","journal-title":"Oral Oncol"},{"key":"pone.0315001.ref047","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1592\/phco.23.9.15S.32889","article-title":"Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy[J]","volume":"23","author":"J Crawford","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"1","key":"pone.0315001.ref048","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","article-title":"The five \"Ws\" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)[J]","volume":"89","author":"M Lambertini","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"pone.0315001.ref049","first-page":"55","article-title":"The role of biochemical mediators in peripheral nociception and bone pain[J]","volume":"7","author":"A. Bennett","year":"1988","journal-title":"Cancer Surv"},{"issue":"7","key":"pone.0315001.ref050","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00520-016-3119-0","article-title":"Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim[J]","volume":"24","author":"J Moukharskaya","year":"2016","journal-title":"Support Care Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0315001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:44:36Z","timestamp":1736966676000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0315001"}},"subtitle":[],"editor":[{"given":"Halvard","family":"B\u00f6nig","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0315001","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]}}}